Effect of Prolyl Endopeptidase on Digestive-Resistant Gliadin Peptides in Vivo
- 13 May 2004
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 311 (1), 213-219
- https://doi.org/10.1124/jpet.104.068429
Abstract
Many gluten peptides elicit proliferative responses from T cells from Celiac Sprue patients, influencing the pathogenesis of this small intestinal disorder. These peptides are Pro- and Gln-rich in character, suggesting that resistance to proteolysis promotes their toxicity. To test this hypothesis, we analyzed the digestive resistance of a panel of α- and γ-gliadin peptides believed to induce toxicity via diverse mechanisms. Most were highly resistant to gastric and pancreatic protease digestion, but they were digested by intestinal brush-border peptidases. In some instances, there was accumulation of relatively long intermediates. Control peptides from gliadin and myoglobin revealed that digestive resistance depended on factors other than size. Prolyl endopeptidase (PEP) supplementation substantially reduced the concentrations of these peptides. To estimate a pharmacologically useful PEP dose, recombinant PEP was coperfused into rat intestine with the highly digestive-resistant 33-mer peptide LQLQPF(PQPQLPY)3 PQPQPF (PEP: peptide weight ratio 1:50 to 1:5). PEP dosing experiments indicate significant changes in the average residence time. The in vivo benefit of PEP was verified by coperfusion with a mixture of 33-mer and partially proteolyzed gliadin. These data verify and extend our earlier proposal that gliadin peptides, although resistant to proteolysis, can be processed efficiently by PEP supplementation. Indeed, PEP may be able to treat Celiac Sprue by reducing or eliminating such peptides from the intestine.Keywords
This publication has 22 references indexed in Scilit:
- Alterations of the intestinal transport and processing of gliadin peptides in celiac diseaseGastroenterology, 2003
- Association between innate response to gliadin and activation of pathogenic T cells in coeliac diseaseThe Lancet, 2003
- Hla types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the european genetics cluster on celiac diseaseHuman Immunology, 2003
- The Intestinal T Cell Response to α-Gliadin in Adult Celiac Disease Is Focused on a Single Deamidated Glutamine Targeted by Tissue TransglutaminaseThe Journal of Experimental Medicine, 2000
- Serum immunoglobulin a from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiationGastroenterology, 1999
- Partial In Vitro Digestion of Active Gliadin-Related Peptides in Celiac DiseaseProtein Journal, 1998
- Coeliac diseaseThe Lancet, 1997
- In vitro mucosal digestion of synthetic gliadin-derived peptides in celiac diseaseProtein Journal, 1995
- D 600 block of L-type Ca2+ channel in vascular smooth muscle cells: comparison with permanently charged derivative, D 890American Journal of Physiology-Cell Physiology, 1989
- In vitro (Organ culture) studies of the toxicity of specific A-gliadin peptides in celiac diseaseGastroenterology, 1988